Products
8 December 2023
Exciting expansion as SpeeDx adds concise gastroenteritis panels to their Research offerings
EntericPlex* products Sharpen Your Focus SpeeDx have released a suite of gastroenteritis panels, the three EntericPlex RUO assays, each with up to 5 targets in a single-well multiplexed qPCR/NAAT assay⎯differing from...
1 September 2023
SpeeDx releases Compact Respiratory Multiplex in advance of UK winter
Upfront diagnosis. Combat seasonal testing surges with ease PlexPCR® Flu/RSV/SARS-CoV-2 detects Influenza, Respiratory Syncytial Virus and SARS-CoV-2 virus in a single-well multiplex qPCR test. Prompt identification of these viral infections can...
12 July 2023
SpeeDx announce expansion of their research offering.
SpeeDx Pty. Ltd., have released a new Research Use Only (RUO) product providing an exciting expansion of their research offering. CT/GC/TV/MGPlex* simultaneously detects Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), Trichomonas...
1 March 2023
SpeeDx raises $26 million to accelerate new technology development and commercial expansion
Funds will accelerate technology development to increase actionable patient results per test SYDNEY Australia 28 February 2023, SpeeDx Pty. Ltd., a developer of transformative molecular diagnostic solutions, has today announced...
18 October 2022
SpeeDx Supports Papua New Guinea with COVID-19 Tests
Provision of SARS-CoV-2 tests reinforces PNG sovereign capacity to respond to ongoing pandemic. SpeeDx announce they have donated PlexPCR® SARS-CoV-2 tests and PlexPrime® SARS-CoV-2 Genotyping reagents to support Papua New Guinea...
10 October 2022
SpeeDx have added a new product to their portfolio — PlexMonkeypox.
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have added a new product to their portfolio; PlexMonkeypox* a single well, multiplex qPCR that simultaneously detects the Orthopoxvirus L1R...
6 October 2021
SARS-CoV-2 Variant Analysis Portfolio Further Expanded
SpeeDx have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The...
17 August 2021
SARS-CoV-2 Variant Analysis Portfolio Expanded
SpeeDx have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the SARS-CoV-2 Delta variant of concern (VOC), P681R. The recently launched PlexPrime® SARS-CoV-2...
12 August 2021
SpeeDx receives TGA clearance PlexPCR® SARS-CoV-2
SpeeDx Pty. Ltd. announced today their PlexPCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration (TGA). Designed from a database of over 1,000,000 sequences, the two gene, single-well...